Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results

Kyle, Barry D.; Agbor, Terence A.; Shajib, Sharif; Chauhan, Usha; Marshall, John K.; Halder, Smita; Ip, Stephen; Khan, Waliul I.

doi:10.1093/jcag/gwaa009

Cited by 20 publications

(16 citation statements)

References 24 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noted that the placebo/OL’772 group, had a relatively smaller sample size compared with the GSK2982772/OL’772 group and that FCP values at baseline were highly variable. The steep increase observed in the placebo/OL’772 group at day 43 might be explained by one subject who had a large increase from baseline at day 43, likely reflecting a flare which is characteristic of the natural course of disease for patients with ulcerative colitis 25 and impacting the group outcome.…”

Section: Discussionmentioning

confidence: 99%

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

Weisel

Scott

Berger

et al. 2021

BMJ Open Gastroenterol

View full text Add to dashboard Cite

ObjectiveTumour necrosis factor signalling via the receptor-interacting protein kinase 1 (RIPK1) pathway regulates colonic inflammation suggesting that RIPK1 inhibition may be a potential therapeutic target in ulcerative colitis (UC). This phase IIa, randomised, double-blind experimental medicine study investigated the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of the RIPK1 inhibitor GSK2982772 in patients with active UC.DesignIn part A, prior to a protocol amendment, one patient was randomised to receive GSK2982772 60 mg twice daily for 42 days. After the amendment, patients were randomised 2:1 to receive GSK2982772 60 mg or placebo three times daily for 42 days. In part B, all patients switched to open-label GSK2982772 60 mg three times daily for 42 days. Safety, PK, PD biomarkers, histological disease activity, clinical efficacy and quality of life were assessed at days 43 and 85.ResultsThirty-six patients were randomised (n=12, placebo/open-label GSK2982772; n=24, GSK2982772/open-label GSK2982772). Most adverse events were mild, with headache reported the most frequently across groups (placebo/open-label GSK2982772, n=2 (17%); GSK2982772/open-label GSK2982772, n=8 (33%)). GSK2982772 was well distributed into colonic tissue, with generally higher concentrations in colonic biopsy samples versus plasma. No apparent differences between treatment groups were observed for PD, histological disease activity, clinical disease activity or quality-of-life measures. At screening, all patients had Mayo endoscopic scores of 2 or 3. At day 43, no patients in the placebo/open-label GSK2982772 group achieved Mayo endoscopic scores of 0 or 1 vs 3/24 (13%) for GSK2982772/open-label GSK2982772. At day 85, 1/9 (11%) achieved scores of 0 or one for placebo/open-label GSK2982772 vs 3/22 (14%) for GSK2982772/open-label GSK2982772.ConclusionGSK2982772 was generally well tolerated, with no treatment-related safety concerns identified. However, no significant differences in efficacy were observed between treatment groups, suggesting that GSK2982772 as monotherapy is not a promising treatment for patients with active UC.Trial registration numberNCT02903966.

show abstract

Section: Discussionmentioning

confidence: 99%

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

Weisel

Scott

Berger

et al. 2021

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Current blood and serological laboratory tests such as total leukocyte count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), provide indirect, objective but non-speci c markers for UC. Few studies have shown relatively poor sensitivity and speci city for the use of these biomarkers in diagnosing IBD and monitoring treatment [17,18].…”

Section: Discussionmentioning

confidence: 99%

A novel inflammatory indicator in extensive ulcerative colitis; Endocan?

Albayrak

Şebin

2022

Preprint

View full text Add to dashboard Cite

Background and study aim Ulcerative colitis (UC) is an inflammatory bowel disease characterized by mucosal inflammation that starts from the rectum (distal) and extends proximally, involving the entire colon (pancolitis). In this study, we aimed to evaluate the usability of endocan level in determining the extent and severity of disease in patients with ulcerative colitis and to determine whether it can be a candidate marker for noninvasive evaluation and monitoring since there is not enough data in the literature. Materials and Methods Sixty-five people were included in the study, including thirty-five with ulcerative colitis and thirty in the control group. patients with newly diagnosed ulcerative colitis clinically, endoscopically, and histopathologically, without any treatment, and with normal liver and kidney tests were included in the study. Endoscopic scoring of all patients was performed according to the mayo endoscopic scoring (MES) system. Blood samples for CRP (C-reactive protein) and endocan were taken from the patients simultaneously. Results There was a significant statistical difference between all patients with ulcerative colitis and the control group in both endocan level and CRP level (p < 0.001). There was a statistically significant difference between endocan levels and CRP levels between the left-distal group and pancolitis (diffuse colitis) patients, but there was no statistical difference between age and MES. Conclusion Serum endocan level can be a useful test in determining the extent and severity of ulcerative colitis, making hospitalization decisions, and planning treatment. Stool markers may not always be available due to patient compliance.

show abstract

“…S100A12 is expressed as a cytoplasmic protein in neutrophils and has a pro-inflammatory function that includes potent chemotactic activity (44,45). Both expression and secretion of S100A12 are increased in the serum and colon tissues from patients with IBD, and S100A12 levels in feces can be used as an indicator of mucosal healing and disease severity (15,46). For example, S100A12 has 96% specificity for IBS vs. IBD when the threshold was set as 10 mg/kg.…”

Section: Traditional Plasma and Stool Biomarkers Used To Assess Ibd Activitymentioning

confidence: 99%

“…Of these biomarkers, fecal calprotectin (FC) correlates best with the number of active inflammation sites reported from biopsy than serum CRP and white blood cell count (15). Erythrocyte sedimentation rate (ESR), platelet count, and serum albumin level are also used to help assess IBD inflammation (54,55), though they are not particularly accurate measures of the disease.…”

Section: Traditional Plasma and Stool Biomarkers Used To Assess Ibd Activitymentioning

confidence: 99%

Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease

Guo

Huang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is characterized by relapse and remission alternately. It remains a great challenge to diagnose and assess disease activity during IBD due to the lack of specific markers. While traditional biomarkers from plasma and stool, such as C-reactive protein (CRP), fecal calprotectin (FC), and S100A12, can be used to measure inflammation, they are not specific to IBD and difficult to determine an effective cut-off value. There is consensus that gut microbiota is crucial for intestinal dysbiosis is closely associated with IBD etiopathology and pathogenesis. Multiple studies have documented differences in the composition of gut microbiota between patients with IBD and healthy individuals, particularly regarding microbial diversity and relative abundance of specific bacteria. Patients with IBD have higher levels of Proteobacteria and lower amounts of Bacteroides, Eubacterium, and Faecalibacterium than healthy individuals. This review summarizes the pros and cons of using traditional and microbiota biomarkers to assess disease severity and treatment outcomes and addresses the possibility of using microbiota-focused interventions during IBD treatment. Understanding the role of microbial biomarkers in the assessment of disease activity and treatment outcomes has the potential to change clinical practice and lead to the development of more personalized therapies.

show abstract

Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results

Cited by 20 publications

References 24 publications

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

A novel inflammatory indicator in extensive ulcerative colitis; Endocan?

Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease

Contact Info

Product

Resources

About